Abstract
Coronavirus disease 2019 (COVID-19) is an ongoing global health threat. However, currently, no standard therapy has been approved for the disease. To evaluate the clinical effectiveness of convalescent plasma (CP) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19. Retrospective study conducted at Kayseri City Education and Research Hospital, Kayseri, Turkey. The case group consisted of adult patients (> 18 years) with ARDS due to COVID-19 who received CP in combination with antiviral and supportive treatment. These patients were compared with others who only received antiviral and supportive treatment. During the study period, a total of 30 patients with ARDS due to COVID-19 were included. Eleven patients (36%) received CP in combination with antiviral and supportive treatment, whereas nineteen patients (64%) in the control group only received antiviral and supportive treatment. On admission, the median age, demographic and clinical data and initial laboratory test results were similar between the groups (P > 0.05). On the 14th day of treatment, the laboratory values remained similar between the groups (P > 0.05). The mortality rates were not significantly different between the groups. CP treatment did not affect mortality or lead to clinical improvement for COVID-19 patients with ARDS.
Highlights
At the end of 2019, a novel coronavirus was recognized as a cause of viral pneumonia cases in Wuhan, China
Adult patients (> 18 years) who were treated in the intensive care unit (ICU) for acute respiratory distress syndrome (ARDS) due to COVID-19 were included to this study
A total of 30 patients with COVID-19-related ARDS were included in this study
Summary
At the end of 2019, a novel coronavirus was recognized as a cause of viral pneumonia cases in Wuhan, China. There is no proven effective treatment for COVID-19.4 Convalescent plasma (CP) treatment is one of the passive immunotherapy methods used. This is a very old procedure.[5] It was used successfully against SARS-CoV in 2003, the influenza A pandemic (H1N1) in 2009, Middle East respiratory syndrome coronavirus in 2012, and Ebola virus in 2015. CP was shown to have reduced the mortality rate among highrisk COVID-19 patients.[10] On the other hand, in another study, a meta-analysis comparing CP therapy with placebo did not demonstrate any evidence of benefit from use of CP compared with placebo or standard care, with regard to clinical improvement or reduction of all-cause mortality.[11]. EOrRenIGEI,NUAluL-KAıRlıçTAIC, LKEor|kEmreanzES,,UYıllud-ıKzıMlıç, AYü, KksoerlkRmCa,zKSıl,ınYçıl-dTıozkMer, YAü, kAsreml RanC-,FKırılaınt çE-,TBoeksetreApe, A-Drmurasnu-nFıZra, tÇEe,liBkeIstepe-Dursun Z, Çelik I
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
